Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
20. Juni 2024 09:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical...
Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo
13. Oktober 2020 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
03. September 2020 08:30 ET
|
Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...
Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
29. Juli 2020 08:30 ET
|
Auris Medical AG
Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
06. Februar 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
White Gold Corp. Extends Discovery Hole to 22.5 g/t Gold and 154.0 g/t Silver over 30.5m, Trenches 66.39 g/t Gold and 302 g/t Silver over 5m, including 109.9 g/t Gold and 486.4 g/t Silver over 3m Confirming Zone Continuity on Vertigo, JP Ross
06. Dezember 2018 09:17 ET
|
White Gold Corp.
TORONTO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the "Company) is pleased to announce additional Reverse Circulation (“RC”) drill results...
White Gold Corp. Drills 103.9 g/t Gold & 400.0 g/t Silver over 1.52m from Surface within a Broader Intercept of 31.4 g/t Gold over 6.1m and Identifies New High-Grade Gold Zones at Vertigo Target on JP Ross Property
15. November 2018 08:00 ET
|
White Gold Corp.
TORONTO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the "Company) is pleased to announce additional Rotary-Air-Blast (“RAB”) and Reverse...
Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere's Disease
01. Dezember 2014 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...